Company intelligence / Profile preview

DB Pharm Korea

Seoul, Seoul, South Korea

Ownership: Private
Development stage: Other

Overview

DB Pharm Korea has brought several globally recognized medications to the Korean market, including branded injectable ibuprofen (Caldolor®, by Cumberland Pharmaceuticals), cytarabine, pentamidine, and pentostatin, with regulatory and commercial distribution in place.

Therapeutic areas: Infectious DiseasesOncologyNeurology
Modalities: Small molecule
Industry: Non-Academic Healthcare

Partnerships

Cumberland Pharmaceuticals (distribution, Caldolor®)Zenics Korea (local distribution partnership for Caldolor®)Hospira (promotion agreement for cytarabine, pentamidine, pentostatin)

Beyond the preview

Go deeper on DB Pharm Korea.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DB Pharm Korea.

Explore the full profile